Author

I. Collins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

H. D. Thomas· 2 shared H. Sellier· 2 shared J. A. Butterworth· 2 shared J. E. Hunter· 2 shared M. D. Garrett· 2 shared N. D. Perkins· 2 shared S. Luli· 2 shared A. A. Antolin· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. D. Thomas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway

J. E. Hunter, A. E. Campbell, N. L. Hannaway, S. Kerridge, S. Luli, J. A. Butterworth, H. Sellier, R. Mukherjee, H. D. Thomas, P. J. Brownridge, J. Coxhead, L. Taylor, P. Leary, M. S. R. Hasoon, I. Collins, , N. D. Perkins

The paper identifies a c-Rel and USP1 dependent pathway that regulates CHK1 inhibitor resistance in lymphoma cells.

bioRxiv · May 26, 2021Cancer Biology

Evolution of kinase polypharmacology across HSP90 drug discovery

A. A. Antolin, P. A. Clarke, I. Collins, P. Workman, B. Al-Lazikani

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

bioRxiv · Sep 9, 2020Pharmacology & Toxicology

Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase

K. Pollock, M. Liu, M. Zaleska, M. Pfuhl, I. Collins, S. Guettler

This study identifies fragment molecules targeting tankyrase's substrate-binding ankyrin repeat domains through biophysical assays, offering potential new therapeutic approaches for cancer.

bioRxiv · Mar 4, 2019Biophysics

Regulation of checkpoint kinase signalling and tumorigenesis by the NF-κB regulated gene, CLSPN

J. E. Hunter, J. A. Butterworth, H. Sellier, S. Luli, A. Floudas, A. J. Moore, H. D. Thomas, K. J. Campbell, N. S. Kenneth, R. T. Chiremba, D. Tiniakos, A. M. Knight, B. E. Gewurz, F. Oakley, M. D. Garrett, , N. D. Perkins

This study shows that CLSPN, regulated by NF-κB, influences checkpoint kinase signalling and tumorigenesis, with implications for cancer treatment resistance and biomarker potential.

bioRxiv · Jun 28, 2018 · PreprintCancer Biology